Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

279
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
279

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Ivosidenib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2024
Same author

Pemigatinib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2024
Same author

Ivosidenib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2023
Same author

Epcoritamab: First Approval.

Drugs·2023
Same author

Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.

Drugs·2023
Same author

Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.

Drugs·2023

Related Experiment Video

Updated: Feb 4, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

SB5: An Adalimumab Biosimilar.

James E Frampton1

  • 1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|September 26, 2018
PubMed
Summary
This summary is machine-generated.

SB5 is a biosimilar to adalimumab, demonstrating equivalent efficacy and similar safety, tolerability, and immunogenicity profiles in rheumatoid arthritis patients. Switching from adalimumab to SB5 showed no negative impact, offering a comparable treatment option.

More Related Videos

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model
10:11

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model

Published on: March 7, 2013

15.8K
In Vitro Assay to Study Tumor-macrophage Interaction
08:36

In Vitro Assay to Study Tumor-macrophage Interaction

Published on: August 1, 2019

8.0K

Related Experiment Videos

Last Updated: Feb 4, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model
10:11

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model

Published on: March 7, 2013

15.8K
In Vitro Assay to Study Tumor-macrophage Interaction
08:36

In Vitro Assay to Study Tumor-macrophage Interaction

Published on: August 1, 2019

8.0K

Area of Science:

  • Immunology
  • Pharmacology
  • Rheumatology

Background:

  • Adalimumab is a widely used anti-TNF monoclonal antibody for various inflammatory conditions.
  • Biosimilars offer potential for increased treatment accessibility and cost-effectiveness.
  • SB5 is a biosimilar referencing adalimumab.

Purpose of the Study:

  • To evaluate the efficacy, safety, tolerability, and immunogenicity of SB5 compared to reference adalimumab.
  • To assess the impact of switching from adalimumab to SB5.

Main Methods:

  • Physicochemical, pharmacodynamic, and pharmacokinetic comparisons between SB5 and adalimumab.
  • Clinical trials in rheumatoid arthritis (RA) patients to assess efficacy and safety.
  • Immunogenicity assessment and evaluation of switching effects.

Main Results:

  • SB5 demonstrated similar physicochemical and pharmacodynamic properties to adalimumab.
  • Pharmacokinetic similarity was confirmed in healthy volunteers and RA patients.
  • SB5 showed equivalent clinical efficacy and a similar safety, tolerability, and immunogenicity profile to adalimumab in RA patients.
  • Switching from adalimumab to SB5 did not impact efficacy, safety, or immunogenicity.

Conclusions:

  • SB5 is a clinically effective biosimilar alternative to adalimumab for approved indications.
  • SB5 offers comparable therapeutic benefits with similar safety and immunogenicity profiles.
  • The established role of adalimumab supports SB5 as a viable treatment option.